Clinical trial
[14C] -RV521.HCl - A Phase 1, Open-label Study of the Absorption, Metabolism, and Excretion Following a Single Oral Dose in Healthy Male Subjects
NCT05873764 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- [14C] -RV521.HCl - A Phase 1, Open-label Study of the Absorption, Metabolism, and Excretion Following a Single Oral Dose in Healthy Male Subjects
- Lead sponsor
- Pfizer
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- May 25, 2022
- Completion date
- July 12, 2022
- Enrollment
- 9 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.